



Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma

Information for the public Published: 15 May 2024

www.nice.org.uk

Selinexor (Nexpovio) with bortezomib and dexamethasone is available on the NHS. It is a possible treatment for multiple myeloma in adults who:

- have only had 1 previous line of treatment, and their condition has stopped responding to both daratumumab and lenalidomide, or
- have only had 2 previous lines of treatment and their condition has stopped responding to lenalidomide.

If you are not eligible for selinexor with bortezomib and dexamethasone but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on multiple myeloma may be a good place to find out more.

These organisations can give you advice and support:

- Myeloma UK, 0800 980 3332
- Blood Cancer UK, 0808 2080 888
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6135-1